Patents by Inventor Adnan M. M. Mjalli

Adnan M. M. Mjalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 8987295
    Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: March 24, 2015
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
  • Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
    Patent number: 8946259
    Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: February 3, 2015
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, David Robert Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff Jiqun Zhu, Mohan Rao, Robert Carl Andrews, Tan Ren
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 8933222
    Abstract: The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: January 13, 2015
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors
    Publication number: 20140371250
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Application
    Filed: September 4, 2014
    Publication date: December 18, 2014
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Rage fusion proteins and methods of use
    Patent number: 8877192
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: November 4, 2014
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 8853226
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: October 7, 2014
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20140200212
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Applicant: High Point Pharmaceuticals, LLC
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Oxadiazoanthracene Compounds for the Treatment of Diabetes
    Publication number: 20140187769
    Abstract: The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and methods of synthesizing precursors to these oxadiazoanthracene derivatives.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 3, 2014
    Applicant: TransTech Pharma, LLC
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 8759535
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: June 24, 2014
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 8703766
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: April 22, 2014
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors
    Publication number: 20140066477
    Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 6, 2014
    Applicant: High Point Pharmaceuticals, LLC
    Inventors: Adnan M.M. Mjalli, David Robert Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff Jiqun Zhu, Mohan Rao, Robert Carl Andrews, Tan Ren
  • Benzazole derivatives, compositions, and methods of use as ?-secretase inhibitors
    Patent number: 8598353
    Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: December 3, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, David R. Jones, Devi Reddy Gohimukkula, Guoxiang Huang, Jeff J. Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
  • OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES
    Publication number: 20130317015
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 28, 2013
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
    Patent number: 8563742
    Abstract: Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: October 22, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Robert C. Andrews, Samuel Victory, Suparna Gupta
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 8524708
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: September 3, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as ?-secretase inhibitors
    Patent number: 8450354
    Abstract: The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 28, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Mohan Rao, Raju Bore Gowda, Robert Carl Andrews, Rongyuan Xie, Soumya P. Sahoo, Tan Ren, William Kenneth Banner
  • Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors
    Patent number: 8404731
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: March 26, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 8383644
    Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: February 26, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James Quada, Jennifer L. R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
  • Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
    Patent number: 8377983
    Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: February 19, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu
  • Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
    Patent number: 8350039
    Abstract: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: January 8, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Pingzhen Wang, Robert Carl Andrews, Rongyuan Xie, Tan Ren